Avenge Bio

📍 Natick, United States🗓 Founded 2019👥 22 employees💰 Last funded Jan 2022
Biotechnology🌐 avengebio.com
Website LinkedIn
Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2019
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Avenge Bio?
Avenge Bio has 1 investors on record on gritt.io, 1 mid-stage.
When did Avenge Bio last raise funding?
The most recent investment in Avenge Bio recorded on gritt.io was in January 2022.
When was Avenge Bio founded?
Avenge Bio was founded in 2019.
What industry is Avenge Bio in?
Avenge Bio operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Avenge Bio based?
Avenge Bio is headquartered in Natick, United States.